Payment overview · 2025
General Payments
$257.06
14 reported records · 10 companies
Healthcare provider profile · identity verified
Donny Hardy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BEREA, KY · NPI 1811981533
Verified facts
What the public records show
CMS Open Payments records show Donny Hardy, MD received $257.06 in general payments during 2025 across 14 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.27 | 21.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.89 | 15.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.12 | 13.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.34 | 9.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.12 | 8.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $19.65 | 7.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.58 | 6.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.46 | 6.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.98 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.65 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $257.06 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.27 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 592 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 501 | 147 |
| Lisinopril | Lisinopril | 461 | 135 |
| Gabapentin | Gabapentin | 402 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 115 |
| Omeprazole | Omeprazole | 387 | 107 |
| Losartan Potassium | Losartan Potassium | 344 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 88 |
| Potassium Chloride | Potassium Chloride | 259 | 65 |
| Carvedilol | Carvedilol | 243 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 242 | 74 |
| Metformin Hcl | Metformin Hcl | 226 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 67 |
| Sertraline Hcl | Sertraline Hcl | 186 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 51 |
| Trazodone Hcl | Trazodone Hcl | 175 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 43 |
| Furosemide | Furosemide | 145 | 52 |
| Allopurinol | Allopurinol | 142 | 45 |
| Tramadol Hcl | Tramadol Hcl | 135 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 34 |
| Eliquis | Apixaban | 129 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 42 |
| Montelukast Sodium | Montelukast Sodium | 122 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 35 |
| Metformin Hcl Er | Metformin Hcl | 120 | 36 |
| Lorazepam | Lorazepam | 117 | 16 |
| Finasteride | Finasteride | 110 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 32 |
| Ezetimibe | Ezetimibe | 103 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 19 |
| Alendronate Sodium | Alendronate Sodium | 100 | 26 |
| Glipizide Er | Glipizide | 95 | 26 |
| Mirtazapine | Mirtazapine | 94 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 22 |
| Meloxicam | Meloxicam | 87 | 30 |
| Simvastatin | Simvastatin | 87 | 29 |
| Clonazepam | Clonazepam | 85 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 23 |
| Pregabalin | Pregabalin | 84 | 17 |
| Farxiga | Dapagliflozin Propanediol | 83 | 21 |
| Spironolactone | Spironolactone | 83 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 20 |
| Temazepam | Temazepam | 76 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 33 |
| Jardiance | Empagliflozin | 74 | 22 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Ozempic | Semaglutide | 72 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 36 |
| Buspirone Hcl | Buspirone Hcl | 69 | 19 |
| Bupropion Xl | Bupropion Hcl | 65 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 35 |
| Famotidine | Famotidine | 64 | 21 |
| Trulicity | Dulaglutide | 64 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 60 | 15 |
| Fluconazole | Fluconazole | 59 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 15 |
| Lactulose | Lactulose | 54 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 21 |
| Diazepam | Diazepam | 53 | suppressed |
| Glipizide | Glipizide | 53 | 14 |
| Januvia | Sitagliptin Phosphate | 53 | 18 |
| Baclofen | Baclofen | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 48 |
| Ibuprofen | Ibuprofen | 52 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Alprazolam | Alprazolam | 51 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 49 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 13 |
| Bumetanide | Bumetanide | 47 | 16 |
| Atenolol | Atenolol | 46 | 14 |
| Aripiprazole | Aripiprazole | 45 | 11 |
| Methylprednisolone | Methylprednisolone | 44 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 12 |
| Enalapril Maleate | Enalapril Maleate | 43 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 42 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 28 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Valsartan | Valsartan | 38 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Celecoxib | Celecoxib | 33 | 11 |
| Nystatin | Nystatin | 33 | 18 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 23 |
| Prednisone | Prednisone | 32 | 12 |
| Cefdinir | Cefdinir | 31 | 25 |
| Primidone | Primidone | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 13 |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 21 | 20 |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.06 · 14 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, MOUNJARO, NEXLETOL, Omnipod, QULIPTA, UBRELVY, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error